BACKGROUND: Cell-free DNA is detectable in circulating blood. Numerous reports in the literature have pointed out that cell-free DNA in plasma or serum has the clinical potential to be a more specific tumor marker for the diagnosis and prognosis, as well as the early detection, of cancer. METHODS: In order to adapt cell-free DNA to a routine clinical laboratory test, we used commercial kits such as the QIAamp blood kit for DNA extraction and the PicoGreen DNA kit for DNA quantification. This was done so our results and the normal reference value established would allow to be compared by other laboratories. We have established the normal reference level of cell-free DNA for females and males from age 20-70 years. We also detected elevated cell-free DNA in all cancers that were tested in this study, including carcinomas, leukemia and lymphoma. RESULTS: Our study indicates that the elevation of serum cell-free DNA was usually detected in specimens containing elevated tumor markers and is most likely associated with tumor metastases. The electrophoretic pattern of cell-free DNA showed that cell-free DNA from cancer patient is fragmented, containing smaller DNA (100 bp) not found in normal cell-free DNA. CONCLUSIONS: Measuring cell-free DNA may complement currently used tumor markers for the management of cancer patients.
BACKGROUND: Cell-free DNA is detectable in circulating blood. Numerous reports in the literature have pointed out that cell-free DNA in plasma or serum has the clinical potential to be a more specific tumor marker for the diagnosis and prognosis, as well as the early detection, of cancer. METHODS: In order to adapt cell-free DNA to a routine clinical laboratory test, we used commercial kits such as the QIAamp blood kit for DNA extraction and the PicoGreen DNA kit for DNA quantification. This was done so our results and the normal reference value established would allow to be compared by other laboratories. We have established the normal reference level of cell-free DNA for females and males from age 20-70 years. We also detected elevated cell-free DNA in all cancers that were tested in this study, including carcinomas, leukemia and lymphoma. RESULTS: Our study indicates that the elevation of serum cell-free DNA was usually detected in specimens containing elevated tumor markers and is most likely associated with tumor metastases. The electrophoretic pattern of cell-free DNA showed that cell-free DNA from cancerpatient is fragmented, containing smaller DNA (100 bp) not found in normal cell-free DNA. CONCLUSIONS: Measuring cell-free DNA may complement currently used tumor markers for the management of cancerpatients.
Authors: Jennifer S Chou; John D Jacobson; William C Patton; Alan King; Philip J Chan Journal: J Assist Reprod Genet Date: 2004-11 Impact factor: 3.412
Authors: Elaine A Hart; William C Patton; John D Jacobson; Alan King; Johannah Corselli; Philip J Chan Journal: J Assist Reprod Genet Date: 2005-05 Impact factor: 3.412
Authors: Jennifer D Brooks; Paul Cairns; Roy E Shore; Catherine B Klein; Isaac Wirgin; Yelena Afanasyeva; Anne Zeleniuch-Jacquotte Journal: Cancer Epidemiol Date: 2010-12 Impact factor: 2.984
Authors: Avery Sonnenberg; Jennifer Y Marciniak; James McCanna; Rajaram Krishnan; Laura Rassenti; Thomas J Kipps; Michael J Heller Journal: Electrophoresis Date: 2013-04 Impact factor: 3.535
Authors: Yulia Korshunova; Rebecca K Maloney; Nathan Lakey; Robert W Citek; Blaire Bacher; Arief Budiman; Jared M Ordway; W Richard McCombie; Jorge Leon; Jeffrey A Jeddeloh; John D McPherson Journal: Genome Res Date: 2007-11-21 Impact factor: 9.043
Authors: Corina Kohler; Ramin Radpour; Zeinab Barekati; Reza Asadollahi; Johannes Bitzer; Edward Wight; Nicole Bürki; Claude Diesch; Wolfgang Holzgreve; Xiao Yan Zhong Journal: Mol Cancer Date: 2009-11-17 Impact factor: 27.401